What's Hot

View all perspectives
      A#2363
      Deodhar
      Bimekizumab fast time to work:
      BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as

      Eric Dein ericdeinmd

      1 month ago
      A#2363 Deodhar Bimekizumab fast time to work: BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose. @RheumNow #ACR24 https://t.co/T81Lzyoy7m
      Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5

      Richard Conway RichardPAConway

      1 month ago
      Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3
      Disease specific chatbots might be primetime - investigators from NYC made the a #LupusCoach chatbot - patients indicate

      Bella Mehta bella_mehta

      1 month ago
      Disease specific chatbots might be primetime - investigators from NYC made the a #LupusCoach chatbot - patients indicated high levels of satisfaction and were excited about it. @rheumnow abst#2160 #ACR24
      In the horizon for Knee #OA pain management - XG005 - non opioid inhibiting inflammatory and neuropathic signals via the

      Bella Mehta bella_mehta

      1 month ago
      In the horizon for Knee #OA pain management - XG005 - non opioid inhibiting inflammatory and neuropathic signals via the COX enzymes and the calcium subunit. Phase 2b , placebo control, double blind study Abst #L08 #ACR24 @RheumNow https://t.co/j4qkj1Xvbr
      Implantable Vagus Nerve Stimulator for RA
      1 month ago
      Reproductive Issues in axSpA: Fertility and Pregnancy

      axSpA affects young patients with symptom onset occurring in earl

      Dr. John Cush RheumNow

      1 month ago
      Reproductive Issues in axSpA: Fertility and Pregnancy axSpA affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their… https://t.co/8tLFOvFqdO https://t.co/E3AOOCHTgu
      Ahmadzay et al. Real world secukinumab in PsA data in 1202 patients. Smokers/ex-smokers have 30% lower treatment retenti

      Richard Conway RichardPAConway

      1 month ago
      Ahmadzay et al. Real world secukinumab in PsA data in 1202 patients. Smokers/ex-smokers have 30% lower treatment retention. But if they maintain treatment, appear to respond equally well. BMI no effect. @RheumNow #ACR24 Abstr#2350 https://t.co/XVPmEBbRu8 https://t.co/QyJirWRKvq
      A#2291
      ESSDAI does not correlate to PROMISE (pt outcomes) in Sjogrens
      Symptomatology is complex in SjD and beyond tradi

      Eric Dein ericdeinmd

      1 month ago
      A#2291 ESSDAI does not correlate to PROMISE (pt outcomes) in Sjogrens Symptomatology is complex in SjD and beyond traditional disease activity markers @RheumNow #ACR24 https://t.co/AhstAFjOVS
      Abstract 1873: The impact of urbanization on lupus nephritis mortality is complex.
      Race/ethnicity + income modify the e

      Akhil Sood MD AkhilSoodMD

      1 month ago
      Abstract 1873: The impact of urbanization on lupus nephritis mortality is complex. Race/ethnicity + income modify the effects - Income ≥$50k + living in suburbs associated with lower odds of mortality due to LN in racial/ethnic minorities @RheumNow #ACR24
      Abstract 1925: Caution w/ ADI as proxy for neighborhood disadvantage
      - ↑ ADI didn’t correlate with ER visits or ho

      Akhil Sood MD AkhilSoodMD

      1 month ago
      Abstract 1925: Caution w/ ADI as proxy for neighborhood disadvantage - ↑ ADI didn’t correlate with ER visits or hospitalizations, but ↓ Childhood Opportunity Index (COI) did: ER visits: aOR 2.85 (95%CI 1.12-7.26) Hospitalizations: aOR 4.15 (95%CI 1.25-13.81) @RheumNow #ACR24 https://t.co/dVZi8oqBnI
      Harkins @DrTrishHarkins et al. Impact of AC joint OA in PMR. 67% of PMR have AC joint OA. Those who do have worse pain a

      Richard Conway RichardPAConway

      1 month ago
      Harkins @DrTrishHarkins et al. Impact of AC joint OA in PMR. 67% of PMR have AC joint OA. Those who do have worse pain and fatigue scores. @RheumNow #ACR24 Abstr#1974 https://t.co/vAqVuQ5Jzm https://t.co/zx5MMtWdBE
      US biosimilar exp
      Interchangeable biosimilar - can substitute for reference product wo consulting MD
      Primary endpt: phar

      Eric Dein ericdeinmd

      1 month ago
      US biosimilar exp Interchangeable biosimilar - can substitute for reference product wo consulting MD Primary endpt: pharmacokinetic data 61 approved biosimilars @RheumKay: “pts should share in financial benefits” Currently 5-87% discount #PBMReform @ACRheumDC @RheumNow #ACR24 https://t.co/RqwbZalZko
      In their cohort, Dr. Abarza et al reported a small percentage of pts developing PsA before Pso (8.6%)
      This group also ha

      sheila RHEUMarampa

      1 month ago
      In their cohort, Dr. Abarza et al reported a small percentage of pts developing PsA before Pso (8.6%) This group also had faster radiographic progression vs. the Pso before PsA group.....something to consider when evaluating these pts. @rheumnow #ACR24 abs2328 https://t.co/YPcAaKFS2I
      Quote of the day. “Time is kidney” Maria Dall’Era MD, UCSF at the ACR SLE guidelines for management of lupus nephr

      Antoni Chan MD (Prof) synovialjoints

      1 month ago
      Quote of the day. “Time is kidney” Maria Dall’Era MD, UCSF at the ACR SLE guidelines for management of lupus nephritis @RheumNow #ACR24 https://t.co/rz9AhPS2cl
      A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 p

      Antoni Chan MD (Prof) synovialjoints

      1 month ago
      A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes Key findings: - Significant weight loss after starting IL17i, IL23i, and csDMARDs. - TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn

      Podcasts

      • Bah Humbug Vitamin D (12.20.2024)
      • 54K Peptic Ulcers Annually (12.13.2024)
      • Don’t Buy Guitars (12.6.2024)

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright 2024 All Rights Reserved.

      ×